Sharma Munish, Joshi Sushil, Banjade Prakash, Ghamande Shekhar A, Surani Salim
Division of Pulmonary, Critical Care and Sleep Medicine, Baylor Scott and White Medical Center, Temple, Texas.
Department of Medicine, Mantra Hospital and Research Center, Kanchanpur, Nepal. Nepalese Army Institute of Health Science, Kathmandu, Nepal.
Open Respir Med J. 2024 Jan 10;18:e18743064279064. doi: 10.2174/0118743064279064231227070344. eCollection 2024.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report is an essential resource for all clinicians who strive to provide optimal care to patients with chronic obstructive lung disease (COPD). The annual report of GOLD makes few revisions and updates besides including data from the preceding year. At an interval, GOLD comes up with a significant modification in its guidelines, which is generally a major overhaul of the pre-existing guidelines. According to the latest 2023 updates, published in November 2022, there have been significant advancements made in the field of COPD. These include the development of more precise definitions for COPD and its exacerbations, the introduction of a new set of parameters to measure exacerbation severity, and updating the COPD assessment tool. Additionally, revisions have been made to the initial and follow-up treatment guidelines. The report also simplifies the treatment algorithm and sheds light on new findings that suggest the use of pharmacological triple therapy can reduce mortality rates. Furthermore, the report includes discussions on inhaler device selection and adherence to COPD medications. These improvements demonstrate a continued effort to enhance COPD treatment and management. Although there are some areas that could benefit from more detailed guidance and explanation, such as the proper utilization of blood eosinophil counts for treatment decisions, and the establishment of treatment protocols post-hospitalization, the latest modifications to the GOLD recommendations will undoubtedly aid healthcare providers in addressing any gaps in patient care. We aim to highlight key changes in the GOLD 2023 report and present a viewpoint about their potential implications in a real-world clinical scenario.
慢性阻塞性肺疾病全球倡议（GOLD）报告是所有致力于为慢性阻塞性肺疾病（COPD）患者提供最佳治疗的临床医生的重要资源。GOLD的年度报告除了纳入上一年的数据外，几乎没有修订和更新。每隔一段时间，GOLD就会对其指南进行重大修改，通常是对现有指南的全面修订。根据2022年11月发布的2023年最新更新，COPD领域取得了重大进展。这些进展包括对COPD及其急性加重的定义更加精确，引入了一套新的参数来衡量急性加重的严重程度，以及更新了COPD评估工具。此外，对初始治疗和后续治疗指南也进行了修订。该报告还简化了治疗算法，并揭示了新的研究结果，表明使用药物三联疗法可以降低死亡率。此外，报告还包括关于吸入器装置选择和COPD药物依从性的讨论。这些改进表明在不断努力加强COPD的治疗和管理。尽管有些领域可能需要更详细的指导和解释，比如在治疗决策中正确利用血液嗜酸性粒细胞计数，以及制定出院后的治疗方案，但GOLD建议的最新修改无疑将有助于医疗服务提供者弥补患者护理中的任何差距。我们旨在突出GOLD 2023报告中的关键变化，并就其在实际临床场景中的潜在影响提出观点。
